How safe is GlaxoSmithKline plc’s dividend?

Are dividends built to endure at GlaxoSmithKline plc (LON: GSK), or is trouble ahead?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) is one of the largest firms listed in the FTSE 100 by market capitalisation and as such, is bound to attract the attention of dividend-seeking investors.

One market aphorism has it that income strategies tend to beat growth strategies. So it could pay to seek out at least some reliable dividend generators when building a portfolio of shares.

At first glance, GlaxoSmithKline seems attractive. Today’s share price around 1,644p throws up a forward dividend yield of almost 4.9% for 2017.

Should you invest £1,000 in Greggs Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Greggs Plc made the list?

See the 6 stocks

A defensive sector with issues

Big firms such as GlaxoSmithKline in the pharmaceuticals sector tend to have business models similar to consumer goods businesses in other sectors. Whenever a company comes up with a product that customers buy, use up, and buy again repeatedly, cash generation can be reliable and predictable for the business. In the case of GlaxoSmithKline, customers rarely forego their medicines so, in theory, the firm enjoys the defensive, cash-generating qualities that we should be looking for in a dividend investment.

By now, you will probably already be familiar with the so-called patent cliff faced by big pharmaceuticals firms over recent years. Several of GlaxoSmithKline’s big-selling and profitable lines all came to the end of their patent protection periods at around the same time, opening the way for generic competition to swoop into the market with cut-price offerings. The effect on GlaxoSmithKline’s profits was significant. Earnings per share fell for the last four years, first by 2% then by 3%, 12% and a massive 21%.

The company fought the patent-expiry issue by bearing down on costs and working hard to develop new potential blockbuster drugs from its research and development pipeline. The measures are taking effect, and City analysts predict a return to earnings growth during 2016, with EPS up around 27%. That’s encouraging. 

Keeping the faith

Consumer goods firms in other sectors, such as Unilever, don’t rely on patent protection so much as on the strength of their brands to attract customers. So even though profits might be lower than previously enjoyed, I think it’s reasonable to assume that GlaxoSmithKline can still be a reliable cash generator and a solvent business even when challenged by competition. I wonder if such thinking is what kept well-known fund manager Neil Woodford invested in GlaxoSmithKline when the shares were down near 1,000p during 2009?

I looked at the shares myself back then but didn’t have Neil Woodford’s insight. I wish I had because a 64% capital gain plus generous dividend income over the last seven years isn’t to be sniffed at. All that was achieved during a period of crisis and falling earnings, remember, so what might happen when things are going well for the business? Such can be the power of good dividend-paying defensives.   

The dividend payout rose a little each year until 2015 when the directors held it at 2014’s level of 80p per share. By then, adjusted earnings per share dipped slightly below the level of the dividend, so it was prudent not to raise the payout further. In recent guidance, the firm told us it intends to maintain the dividend at 80p per share for 2016 and 2017 too. As cash flow and earnings rebuild — and the outlook is positive — I think right now could be a good time to add GlaxoSmithKline to a portfolio for income.

But there are other promising opportunities in the stock market right now. In fact, here are:

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

piggy bank, searching with binoculars
Investing Articles

An underrated value stock? I think investors should take a closer look

This value stock appears overlooked by the market. And that’s quite rare right now as the stock market recovers from…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Up 35% in a month! But is this electrifying UK growth share a total gamble?

Harvey Jones wishes he'd had a flutter on gaming group Entain last year, as it's now smashing the FTSE 100.…

Read more »

Investing Articles

Should I buy the most popular FTSE 100 stock on AJ Bell?

Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he…

Read more »

Cargo containers with European Union and British flags reflecting Brexit and restrictions in export and import
Investing Articles

UK shares are booming again as the FTSE recovers! Here’s what I’m watching

Mark Hartley takes a deep dive to see which UK shares are lagging behind in the current market rally. Has…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

I bought 1,779 Legal & General shares 2 years ago – see how much dividend income I’ve got since

Harvey Jones holds Legal & General shares and has been pretty underwhelmed by their performance so far. The dividend is…

Read more »

Middle-aged black male working at home desk
Investing Articles

Is the FTSE 100 set to soar? Here are 3 ways to aim to cash in

My outlook for the FTSE 100 is definitely brightening as we get deeper into 2025. How can we make the…

Read more »

Investing Articles

£10k invested in NatWest shares on the ‘Liberation Day’ dip is today worth…

Harvey Jones looks at how NatWest shares have been knocked off course during recent market turbulence, but are now bouncing…

Read more »

Tariffs and Global Economic Supply Chains
US Stock

£5,000 invested in Nvidia stock just before the tariff news is now worth…

Jon Smith talks through the erratic movements in Nvidia stock over the past six weeks and reveals where an investor…

Read more »